Mesoblast up following patents in US and China
Mesoblast (ASX:MSB) has made gains on the ASX following an announcement it has secured further patents covering its technology in the US and China.
Regenerative medicine company Mesoblast (ASX:MSB) has gained over 5.5% in morning trading, adding to smaller gains throughout the week, following an announcement it has secured new patents in the US and China.
The US patents cover composition-of-matter concerning its mesenchymal precursor cell (MPC) technology and give exclusive rights through to March 2029.
This extends protection over aspects of Mesoblast’s technology by an additional seven years beyond its existing patents, which expire in November 2021.
The Chinese patents cover composition-of-matter for Mesoblast’s MPC products derived from an unlimited range of tissue sources, including bone marrow, adipose tissue, placenta, umbilical cord and dental pulp.
These patents provide protection through until 2025.
Mesoblast (ASX:MSB) lifted 38c to $7.09 in morning trading, which amounts to a 35% increase since 1 January this year.
Last year the company’s share price was rattled by speculation its US partner, Teva Pharmaceuticals, was unenthusiastic about the stem cell technology.
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
How brain stem cells move between resting and active states
Understanding this process is crucial, because it underpins how the brain repairs itself and...
Accurate age estimation with DNA methylation
Using cutting-edge artificial intelligence, scientists created a tool that can determine a...
